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Abstract
Background: Over recent years, a growing interest has developed in microbiota and in the concept of maintaining
a special balance between Lactobacillus and other bacteria species in order to promote women’s well-being. The
aim of our study was to confirm that vaginal Lactobacilli long-lasting implementation in women with HPV-
infections and concomitant bacterial vaginosis or vaginitis might be able to help in solving the viral infection, by
re-establishing the original eubiosis.
Methods: A total of 117 women affected by bacterial vaginosis or vaginitis with concomitant HPV-infections were
enrolled at Department of Gynecological Obstetrics and Urological Sciences, La Sapienza University, Rome, Italy
between February 2015 and March 2016. Women were randomized in two groups, standard treatment
(metronidazole 500 mg twice a day for 7 days or fluconazole 150 mg orally once a day for 2 consecutive days)
plus short-term (3 months) vaginal Lactobacillus implementation (group 1, short probiotics treatment protocol
group, n = 60) versus the same standard treatment plus long-lasting (6 months) vaginal Lactobacillus rhamnosus
BMX 54 administration (group 2, treatment group, n = 57).
Results: After a median follow up of 14 months (range 9–30 months) the chance to solve HPV-related cytological
anomalies was twice higher in probiotic long-term users (group 2) versus short probiotics implementation group
(group 1) (79.4% vs 37.5%, p = 0.041). Moreover, a total HPV-clearance was shown in 11.6% of short schedule
probiotics implementation patients compared to a percentage of 31.2% in vaginal Lactobacilli long term users
(p = 0.044), assessed as negative HPV-DNA test documented at the end of the study period.
Conclusions: The consistent percentage of clearance of PAP-smear abnormalities and HPV-clearance obtained in
long-term treatment group has been interestingly high and encouraging. Obviously, larger and randomized studies
are warranted to confirm these encouraging results, but we believe that eubiosis re-establishment is the key to
tackle effectively even HPV-infection.
Trial registration: Retrospectively registered on PRS NCT03372395 (12/12/2017).
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Background
An increasing interest has been developed in microbiota,
with the belief that probiotics could be able to promote
women’s well-being and illnesses in several ways.
The vaginal microbiota of healthy women consists of a
diversity of anaerobic and aerobic microorganisms
(eubiosis). Lactobacilli are the most widespread and pre-
vailing subpopulation. In some conditions, this balance
can be compromised (dysbiosis) and other microorgan-
isms may grow reducing anti-bacterial defence mecha-
nisms. The loss of this delicate steadiness can move in
numerous directions (pathobiosis), depending on dif-
ferent of factors (hormone levels, douching, sexual
practices, bacterial interactions, host defences, and so
on), promoting disorders such as bacterial vaginosis and
yeast vaginitis, and then endorsing the occurrence of
sexually transmitted diseases.
So, a steady vaginal ecosystem would have the ability
to tackle infections, by maintaining a sort of local equi-
librium between the different microbial subpopulations
inhabiting vaginal micro-environment. Likewise, the mi-
crobial species that populate the vagina would play an
important role in having Lactobacilli as the most re-
markable protagonists of this process. The mechanisms
by which Lactobacilli are able to stabilize the vaginal
microbiota consist of the production of antimicrobial
compounds (hydrogen peroxide, lactic acid, bacteriocin-
like substances) and in the capability to adhere and
compete for adhesion sites in the vagina with other
pathogens [1–3].
Thus, we hypothesized that the development of any
kind of disease/infection might be the result of a transi-
tional process, beginning by compromising the physio-
logical vaginal eubiosis, increasing Lactobacilli-mediated
cytolysis and then reaching the stage of pathobiosis,
when the vaginal ecosystem starts to be defenceless and
becomes vulnerable to a variety of infections.
Although just putative relationships between dysbiosis/
pathobiosis and cancer development/progression have been
observed so far, the long duration of dysbiosis that precedes
this condition and the hypothesis of possible combined ef-
fects with other risk factors, suggests the presence of
greater clinical implications regarding the importance of
microbiota conservation and balance [4–6]. Additionally,
the association of microbial dysbiosis with several cancer
types has been noted mainly in areas surrounded by muco-
sal membranes where bacteria live tightly [7, 8].
Infection with human papillomavirus (HPV) has
been recognized as the major cause of cervical cancer
development [9, 19]. Recently, a potential role of the
vaginal dysbiosis/pathobiosis in promoting cervical
HPV-related alterations and consequently precancer-
ous lesions development through the elevation of pH
has been reported [6, 8–10].
The aim of our study was to investigate if Lactobacillus
rhamnosus BMX 54 (NORMOGIN ®) long-lasting vaginal
application in women with dysbiosis and concomitant
HPV-infections, might be able to have an advantageous
effect on viral infection control, by restoring a stable
microbiota to eubiosis.
To our knowledge this is the first trial in the literature
to assess the efficacy of microbiota balance maintenance
against HPV infections and related alterations.
Methods
This is a pilot study, performed between February 2015
and March 2016 at Department of Gynecological Ob-
stetrics and Urologic Sciences, “Sapienza” University of
Rome. Inclusion criteria were: age > 18 years, docu-
mented BV or yeast vaginitis associated with HPV-
infection documented as PAP-smear abnormalities
(ASCUS, L-SIL or H-SIL histologically demonstrated as
CIN1) and/or positive for HPV-DNA. Exclusion criteria
were: pregnancy or breastfeeding, previous abnormal
PAP-smear, CIN2–3, concomitant malignancies, im-
munological diseases, severe comorbidities, prolonged
corticosteroid treatment.
Bacterioscopic exam, PAP-smear, HPV DNA test and
colposcopy were performed for every enrolled patient at
intake and every 3 months of follow up, when indicated.
Bacterioscopic exam was performed every time by the
same investigator as follows: each vaginal sample was
rehydrated with normal saline solution and plotted
under a phase contrast microscope with 400× magnifica-
tion and an area of 0.016 mm2. The presence of bacteria,
clue cells, number of vaginal leucocytes and other signs
of possible microbial balance alteration/infections were
recorded [11]. Evaluation of pH was made with Litmus
paper test.
PAP-smears were evaluated by dedicated expert pathol-
ogists using the three-tiered CIN classification and
Bethesda terminology [9]. An adequate smear was defined
as a sample of adequate squamous cells with evidence of
transformation zone noted on histologic examination.
HPV infection was detected using polymerase chain
reaction (PCR) amplification of the viral DNA, followed
by dot blot hybridization to identify its relevant subtypes
including HPV 16, 18 and collectively other high-risk
HPV subtypes (31–33–35-39-45-51-52-56-58-59-68).
Colposcopy assessment was performed on the basis of
the terminology introduced by the Nomenclature Com-
mittee of International Federation for Cervical Pathology
and Colposcopy in 2011 [12], identifying as Grade 1
(minor changes) the occurrence of a fine mosaic, fine
punctation, a thin acetowhite epithelium, or an irregular,
geographic border and as Grade 2 (major changes) the
presence of a sharp border, an inner border sign, a ridge
sign, a dense acetowhite epithelium, a coarse mosaic/
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punctation, or cuffed crypt openings. Atypical vessels or
other suspicious signs of invasion (such as fragile vessels,
irregular surface, exophytic lesion, necrosis, ulceration,
tumor or gross neoplasm) were included under Grade 2.
In the absence of abnormal findings, the colposcopic
impression was designated as normal. The squamo-
columnar junction visibility was classified as completely
visible or non-completely visible. The transformation
zone type was classified as type 1 and 2 (completely vis-
ible) or type 3 (not fully visible). Endocervical curettage
was performed when the squamo-columnar junction
was not completely visible. Lesion location was classified
on the basis of histological results as follows: ectocervi-
cal (when the lesion was only present on ectocervical
biopsy), endocervical (when the lesion was present on
endocervical curettage), or ectocervical and endocervical
(when the lesion was present on both).
Patients were consecutively randomized in two groups,
standard treatment plus short-term (3 months) vaginal
Lactobacilli implementation (group 1, n = 60) vs stand-
ard treatment plus long-lasting (6 months) Lactobacilli
administration (group 2, n = 57). Standard initial treat-
ment for bacterial or yeast infections was metronidazole
500 mg (orally twice a day for 7 days) or fluconazole
150 mg (orally once a day for two consecutive days),
respectively (Fig. 1).
We decided to administer probiotics as support to
standard treatment in the short treatment protocol group
as well, considering our encouraging results in vaginal
infections control obtained in a previous study [13].
Lactobacilli were administered by vaginal tablets
containing 104 CFU/tablet freeze-dried Lactobacillus
rhamnosus BMX 54, NORMOGIN ® as follows: once a
day for 10 days, once every 3 days for 20 days and then
once every 5 days for other 2 months in all patients
(probiotics implementation for 3 months comprehen-
sively). On the other hand, patients belonging to long-
term treatment arm (group 2) continued using the same
vaginal tablets once a week for a 5-month period, in-
stead of just 2 months as others. All patients followed
a strict follow-up (every 3 months for 9 months).
HPV-DNA test was repeated at the end of the study
period (Fig. 1).
The study was approved by the Ethical Committee and
written informed consent was obtained from all patients.
Statistical analysis was performed using SPSS software
package (SPSS Inc., Chicago, IL, USA) given as mean
(SD) or number (%) of cases, with 95% confidence inter-
vals (CIs), when suitable. Comparison of quantitative
variables in the two groups considered was performed
using the 2-sample Chi-square and Fisher’s test. The
measures were indicated as mean ± SD and 95% confi-
dence interval. All tests used were 2-tailed. A p value of
<0.05 was considered as statistically significant.
Results
A total of 117 women were included in the study (Fig. 1).
Bacterial vaginosis was diagnosed following Amsel criteria
[14]. Women were diagnosed with yeast vaginitis by the
presence of vaginal discharge in association with at least
one of the distinctive symptoms and signs of the disease
(itching, burning, dyspareunia and dysuria) and by the
presence of yeast infection by at least one of the following
processes: wet mount preparation, Gram-staining or
culture. Only patients with recognized yeast or bac-
terial infection and concomitant PAP smear alteration
or HPV found by PCR analysis were enrolled in the
study. Most of the patients had simultaneous bacterial
Fig. 1 Flow chart. t0: time of inclusion; t3, t6 and t9: follow up time at 3, 6 and 9 months respectively
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vaginosis (55 and 54.4% in Group 1 and 2 respect-
ively). Pap smear abnormalities were associated with
HPV DNA positivity in 58.3 and 57.8% of cases in
Group 1 and 2 respectively. Patients were consecu-
tively randomized in two group as previously ex-
plained (Group 1, n = 60 and Group 2, n = 57).
Mean age in Group 1 was 32.4 years (10.5 SD,
95% CI 29.7–35.1), while in Group 2 it was 29.1 years
(8.9 SD, 95% CI 26.7–31.5). Patients’ baseline
characteristics are shown in Table 1. No significant
differences were seen for any of them between
Groups 1 and 2. A diagram of follow up schedule
was shown in Fig. 1.
Of all participants 84% (n = 98) reported being in a
monogamous heterosexual relationship and 11 women
reported same-sex relationships and eight declared not
having had intercourses at the moment of interview.
Compliance was excellent. All participants came back
for all follow up visits.
Median follow up time was 14 months (range 9–
30 months). After three months, there were no statisti-
cally significant differences between the two groups: re-
mission rates of symptoms and bacterial or yeast
infections related clinical findings were similar in the
two cohorts (Group 1 93.3%, n = 56 and Group 2 96.4%,
n = 55 respectively).
At the end of the study period, the chance to solve
HPV-related cytological anomalies was twice higher
in Lactobacillus rhamnosus BMX 54 long-term vagi-
nal users (79.4%, n = 31 vs 37.5%, n = 15; p = 0.041)
as shown in Fig. 2. Moreover, a total HPV-clearance
was shown in 11.6% (n = 7) of short treatment proto-
col patients compared to a percentage of 31.2% (n =
18) in long-term probiotic users (as negative HPV-
DNA test) after 9 months since treatment starting
(p = 0.044; Fig. 3).
Furthermore, long term probiotics administration
determined also a reduction in vaginal infections recur-
rences as shown in Table 2.
Discussion
The vaginal microbiota plays a significant role in the
female reproductive tract wellness maintenance. Al-
though the human papilloma-virus is highly widespread,
only a small number of women have recurrent HPV in-
fection and subsequently develop precancerous lesions.
An increased variety of vaginal microbiota, combined
with a reduction of Lactobacillus spp., is linked with
HPV infection acquisition and persistence and develop-
ment of cervical pre-cancerous lesions and after years
cancer [15–17]. Cervical cancer is the most common
cancer among women in developing countries and the
second most frequent female tumour worldwide [16].
Commonly, it progresses through a sequence of prema-
lignant lesions known as cervical intraepithelial neopla-
sia (CIN) 1, 2 and 3 [9]. A normal cervical epithelial cell
needs around 10–20 years to become malignant and just
a few women with CIN lesions develop invasive cancer.
HPV is a known risk factor for cervical cancer, but des-
pite the high prevalence of HPV infection, CIN occur-
rence and evolution rates in untreated CIN lesions are
quite low [17, 18]. As acknowledged from the litera-
ture, over 90% of HPV infections and infection-
induced lesions are transient or recurrent and resolve
spontaneously [19, 20]. Although HPV infection plays
a key role in cervical cancer pathogenesis and devel-
poment, other environmental and host factors are in-
volved in endorsing the process, as local microflora
Table 1 Patients’ baseline characteristics
VARIABLES GROUP 1 (n = 60) GROUP 2 (n = 57) p-value
Age, mean ± SD 32.4 ± 10.5 29.1 ± 8.9 NS
Use of contraceptive methods 35 (58.3%) 33 (57.8%) NS
Regular menses 47 (73.3%) 48 (84.2%) NS
Symptoms prevalence (vaginal itching and burning, dyspareunia and dysuria) 53 (88.3%) 49 (85.9%) NS
Smoking 25 (41.6%) 19 (33.3%) NS
Multiple partners 5 (8.3%) 6 (10.5%) NS
Previous deliveries 31 (51.6%) 33 (57.9%) NS
Bacterial vaginosis 33 (55.0%) 31 (54.4%) NS
Yeast vaginitis 27 (45.0%) 26 (45.6%) NS
Pap smear alterations 40 (66.6%) 39 (68.4%) NS
Associated HPV DNA+ 35 (58.3%) 33 (57.8%)
HPV DNA+ alone 20 (33.3%) 18 (31.6%) NS
HPV DNA+ patients (total) 55 (91.7%) 51 (89.4%) NS
HPV DNA negative patients with PAP smear abnormalities 5 (8.3%) 6 (10.5%) NS
NS not significant
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imbalance, immune response deficiency and conse-
quently concomitant vaginal infections [21–24].
Physiologically, a healthy vaginal ecosystem is domi-
nated by Lactobacilli and most of them had also a local
immune system and inflammation response modulation
[25, 26] and by controlling cell proliferation/apoptosis
[27–29].
Hydrogen peroxide, lactate and bacteriocins made by
Lactobacilli play an essential role in vaginal flora balance
and eubiosis by inhibiting further pathogens’ colonization
[13, 30]. Lactobacilli inhibit pathogen overgrowth in the
whole urogenital tract, being a vital support in achieving a
good reproductive and general health in women.
Importance of chronic inflammation in the develop-
ment of pre-cancerous lesions has conquered increasing
attention in the recent years and vaginal infections have
been extensively debated in the literature as a risk factor
for cervical dysplasia [31, 32].
Owing to a defined antitumor effect of probiotics,
their fundamental role in vaginal ecosystem, their
inhibitory effects on pathogens overgrowth and the
relationship between vaginal infections and CIN, we
assumed a possible relationship between vaginal
Lactobacilli deficiency and HPV infections and con-
sequently with HPV related cervical dysplasia.
Lactobacillus rhamnosus vaginal administration was
chosen because it represents the exclusive Lactobacillus
strain that has been recognized as able to colonize hu-
man vaginal microbiota once exogenously applied [26].
Thus, Lactobacilli BMX 54 – a specific selected Lactoba-
cillus strain deposited to Pasteur Institute under
Budapest Treaty –has shown clinical evidence of effect-
iveness when applied vaginally by restoring vaginal bal-
anced ecosystem [33–36].
This study has some limitations the small sample size
and the short follow up even if the statistically signifi-
cant results obtained by using long-term probiotic vagi-
nal administration are interesting and promising. In this
study, cytological and viral endpoints were used to
evaluate a potential effect of vaginal Lactobacilli long-
term implementation in solving cervical abnormalities,
through the establishment of the physiological vaginal
Fig. 2 Trend of HPV abnormalities resolution in the two groups (group 1 – short probiotics implementation group, n = 60; group 2 – long
probiotics implementation group, n = 57; p = 0.041)
Fig. 3 HPV clearance at the end of follow up period (t9) in the two groups (group 1 – short probiotics implementation group, n = 60; group
2 – long probiotics implementation group, n = 57). HPV clearance was significantly higher in long term probiotics users than in the other group
(p = 0.044). t0: before treatment; t9: after 9 months follow up
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balance (eubiosis). The consistent percentage of clear-
ance of PAP-smear abnormalities obtained in vaginal
Lactobacilli long term users group is interesting and
encouraging and it supports our vaginal eubiosis versus
pathobiosis theory.
Conclusions
To our knowledge, this is the first study showing a con-
trol of HPV infection using probiotics. From our data,
probiotics implementation for at least 6 months may be
useful in re-establishing vaginal microflora and due to
the recreation of vaginal balance, seems to benefit in
controlling HPV infection.
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